The phase 3 NRG GU-005 trial did not show a DFS benefit for SBRT vs IMRT in intermediate-risk prostate cancer, but SBRT decreased rectal toxicity. Stereotactic body radiation therapy (SBRT) preserves ...

Physicians and scientists from the UCLA Health Jonsson Comprehensive Cancer Center will share the latest research and clinical trial results at the 2025 American Society for Radiation Oncology (ASTRO) ...

Stereotactic body radiotherapy as salvage therapy after radical prostatectomy was well tolerated. Toxic effects were comparable to a historical cohort of patients receiving conventionally fractionated ...

SBRT after radical prostatectomy without ADT improves prostate cancer BCRFS and appears to be a viable alternative to conventionally fractionated radiation therapy, a phase 2 trial finds. After ...

In men with hormone-sensitive metachronous oligometastatic prostate cancer, the use of stereotactic body radiotherapy (SBRT) commonly delayed the need for long-term ADT and provided durable disease ...

A pooled analysis of five prospective trials showed that stereotactic body radiotherapy (SBRT) was associated with a lower risk for biochemical failure over 10 years vs high-dose rate brachytherapy ...

A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression when they received a ...

Please provide your email address to receive an email when new articles are posted on . Men assigned SBRT reported fewer adverse effects, but longer radiation courses may offer better biochemical ...

For men who undergo a radical prostatectomy for the treatment of prostate cancer, post-surgery radiation therapy can play a vital role in reducing the risk of recurrence. Despite its benefits, many ...

Stereotactic body radiotherapy (SBRT) showed good local control and survival for limited metastatic/progressive cancers. Two-thirds of patients were alive at 2 years with minimal serious toxicity ...

Add Yahoo as a preferred source to see more of our stories on Google. For men facing the return of prostate cancer, a new combination therapy may offer a much longer break before the disease comes ...

The study published by Bastiaan M Privé and colleagues in The Lancet Oncology represents, to our knowledge, the first randomised phase 2 trial evaluating lutetium-177–PSMA-617 (177Lu-PSMA-617) in ...